Article
Medicine, General & Internal
Jiren Yu, Yuan Gao, Li Chen, Dan Wu, Qianyun Shen, Zhicheng Zhao, Weihuai Liu, Hanliang Yang, Qi Zhang, Xinbao Wang, Ping Hu, Zhiqiang Zheng, Xianfa Wang, Hongjun Liu, Zekuan Xu, Zhilong Yan, Yingjie Wu, Mingjuan Jin, Qing Zhang, Xiaosun Liu, Kankai Zhu, Chunhui Shou
Summary: Perioperative chemotherapy is a potential treatment for locally advanced gastric cancer, but the optimal regimen remains unknown. This study compared the safety and efficacy of S-1 plus oxaliplatin (SOX) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX) as perioperative chemotherapy regimens for locally advanced gastric cancer patients. The results showed that SOX was noninferior to FOLFOX and could be recommended as an alternative treatment in Asia.
Article
Oncology
Crystal S. Denlinger, Kristina A. Matkowskyj, Mary F. Mulcahy
Summary: The treatment landscape for gastric and esophageal cancers has been significantly influenced by pivotal trials evaluating immune checkpoint inhibitors (ICIs), leading to changes in NCCN Guidelines. New treatment options such as trastuzumab-deruxtecan (T-DXd) and nivolumab are now recommended for certain patient populations.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Oncology
Shin Saito, Hironori Yamaguchi, Hideyuki Ohzawa, Hideyo Miyato, Rihito Kanamaru, Kentaro Kurashina, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata, Joji Kitayama
Summary: The combination chemotherapy using SOX + IP-PTX regimen showed high efficacy in patients with peritoneal metastases from gastric cancer, with a 1-year overall survival rate of 79.5%. Common toxicities included neutropenia, leukopenia, and anemia, but there were no treatment-related deaths.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Claire Gallois, Qian Shi, Jeffrey P. Meyers, Timothy Iveson, Steven R. Alberts, Aimery de Gramont, Alberto F. Sobrero, Daniel G. Haller, Eiji Oki, Anthony Frank Shields, Richard M. Goldberg, Rachel Kerr, Sara Lonardi, Greg Yothers, Caroline Kelly, Ioannis Boukovinas, Roberto Labianca, Frank A. Sinicrope, Ioannis Souglakos, Takayuki Yoshino, Jeffrey A. Meyerhardt, Thierry Andre, Demetris Papamichael, Julien Taieb
Summary: Whether early discontinuation of all treatment or early discontinuation of oxaliplatin could worsen the prognosis in patients with stage III CC remains unknown.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Chemistry, Analytical
Ting Li, Wei Lu, Hui Tian, Yu Cao, Qianqian He, Xia Chen, Hailong Wang
Summary: A new method using an α-hemolysin nanopore sensor was presented to investigate the adducts of DNA and oxaliplatin. This approach allows for real-time monitoring of the DNA-oxaliplatin condensation process through the detection of nanopore events. The DNA-oxaliplatin adduct can potentially serve as a sensor for detecting oxaliplatin lesions and multiple types of molecules.
ANALYTICAL CHEMISTRY
(2023)
Article
Biochemistry & Molecular Biology
Yan Song, Bo Zhang, Dao Xin, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Jing Li, Qingyu Wang, Jun Zhu, Jing Huang
Summary: In this phase 3 trial, serplulimab plus chemotherapy every 2 weeks significantly improved progression-free survival and overall survival in previously untreated patients with PD-L1-positive advanced esophageal squamous cell carcinoma compared to chemotherapy alone.
Review
Pharmacology & Pharmacy
Shiming He, Jian Xu, Xiujun Liu, Yongsu Zhen
Summary: Esophageal cancer is a common and deadly cancer with two histological subtypes - esophageal squamous cell carcinoma and esophageal adenocarcinoma. Available treatment strategies include surgery, chemotherapy, and molecular targeted therapy, with poor prognosis. This review discusses the latest developments in chemotherapy, molecular targeted therapy, and immunotherapy for esophageal cancer.
ACTA PHARMACEUTICA SINICA B
(2021)
Article
Oncology
Christopher J. LaRocca, Amanda O. Salzwedel, Mizuho Sato-Dahlman, Margarita Romanenko, Rafael Andrade, Julia Davydova, Masato Yamamoto
Summary: An IFN-expressing oncolytic adenovirus driven by the Cox2 promoter demonstrates strong oncolytic effects and cancer-specific replication in esophageal adenocarcinoma (EAC). The virus shows significant tumor growth suppression in xenograft models and selective replication in cancerous tissues in human samples, making it a potential candidate for clinical translation to treat EAC.
ANNALS OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Yoon-Koo Kang, Jeong Hwan Yook, Young-Kyu Park, Jong Seok Lee, Young-Woo Kim, Jin Young Kim, Min-Hee Ryu, Sun Young Rha, Ik Joo Chung, In-Ho Kim, Sang Cheul Oh, Young Soo Park, Taeil Son, Mi Ran Jung, Mi Hwa Heo, Hark Kyun Kim, ChoHyun Park, Chang Hak Yoo, Jin-Hyuk Choi, Dae Young Zang, You Jin Jang, Ji Young Sul, Jong Gwang Kim, Beom Su Kim, Seung-Hoon Beom, Sang Hee Cho, Seung Wan Ryu, Myeong-Cherl Kook, Baek-Yeol Ryoo, Hyun Ki Kim, Moon-Won Yoo, Nam Su Lee, Sang Ho Lee, Gyunji Kim, YeonJu Lee, Jee Hyun Lee, Sung Hoon Noh
Summary: The PRODIGY study demonstrated that neoadjuvant DOS chemotherapy as part of perioperative chemotherapy is effective and well tolerated in Korean patients with LAGC.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Marieke Pape, Pauline A. J. Vissers, Willemieke P. M. Dijksterhuis, David Bertwistle, Laura McDonald, Bianca Mostert, Sarah Derks, Irma M. M. Oving, Rob H. A. Verhoeven, Hanneke W. M. van Laarhoven
Summary: This retrospective cohort study investigated the treatment and survival of patients with advanced esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma (GEJC), and gastric adenocarcinoma (GAC). Despite differences in clinical characteristics and treatment strategies, the survival of patients with advanced EAC, GEJC, and GAC was similar. Therefore, excluding EAC patients from clinical trials for patients with molecularly similar GEJC/GAC should be reconsidered.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Kwan-Ling Yip, Tsen-Ni Tsai, I-Ping Yang, Zhi-Feng Miao, Yen-Cheng Chen, Ching-Chun Li, Wei-Chih Su, Tsung-Kun Chang, Ching-Wen Huang, Hsiang-Lin Tsai, Yung-Sung Yeh, Jaw-Yuan Wang
Summary: Metformin enhances the chemosensitivity of colorectal cancer cells to 5-fluorouracil and oxaliplatin by inducing cell cycle arrest and apoptosis through modulation of mitochondria-related proteins.
Review
Immunology
Yusheng Wang, Wei Yang, Qianyun Wang, Yong Zhou
Summary: Esophageal cancer is a common digestive tract tumor worldwide. Early-stage detection is difficult, with most patients already diagnosed with metastasis. This article reviews the metabolic process of esophageal cancer metastasis and the immune barriers formed by M2 macrophages, CAF, regulatory T cells, and their released cytokines that impede the anti-tumor immune response. The review also discusses the impact of Ferroptosis and summarizes common drugs and research directions in chemotherapy, immunotherapy, and targeted therapy for advanced metastatic esophageal cancer. It aims to provide a foundation for further investigations and management of esophageal cancer metastasis.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Medicine, Research & Experimental
Zahra Asadzadeh, Behzad Mansoori, Ali Mohammadi, Tohid Kazemi, Ahad Mokhtarzadeh, Dariush Shanehbandi, Nima Hemmat, Afshin Derakhshani, Oronzo Brunetti, Sahar Safaei, Marjan Aghajani, Souzan Najafi, Nicola Silvestris, Behzad Baradaran
Summary: The study demonstrated that silencing CD133 reduces the migration and stemness properties of colorectal cancer cells, making the cells more sensitive to Oxaliplatin and lowering the effective dose of the chemical drug. This suppression, when combined with Oxaliplatin treatment, could be a promising therapeutic approach in the treatment of colorectal cancer.
BIOMEDICINE & PHARMACOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Hui Li, Jing Lv, Jing Guo, Shasha Wang, Shihai Liu, Yingji Ma, Zhiwei Liang, Yunyun Wang, Weiwei Qi, Wensheng Qiu
Summary: The combination of 5-FU and TRAIL showed stronger inhibitory effects on the proliferation of gastric cancer cells, with 5-FU enhancing TRAIL-induced gastric cancer cell apoptosis by inactivating the MAPK pathway.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2021)
Article
Multidisciplinary Sciences
Shiliang Liu, Liling Luo, Lei Zhao, Yujia Zhu, Hui Liu, Qiaoqiao Li, Ling Cai, Yonghong Hu, Bo Qiu, Li Zhang, Jingxian Shen, Yadi Yang, Mengzhong Liu, Mian Xi
Summary: "The results of this study show that the addition of induction chemotherapy to definitive chemoradiotherapy does not improve the response rate or survival of patients with unresectable esophageal squamous cell carcinoma."
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Daniel Walden, Selvi Kunnimalaiyaan, Kevin Sokolowski, T. Clark Gamblin, Muthusamy Kunnimalaiyaan
Review
Oncology
Mohamad Bassam Sonbol, Raed Benkhadra, Zhen Wang, Belal Firwana, Daniel J. Walden, Kabir Mody, Joleen M. Hubbard, M. Hassan Murad, Daniel H. Ahn, Tanios Bekaii-Saab
Meeting Abstract
Oncology
Daniel Walden, Fang-Shu Ou, Joseph J. Larson, Christina Wu, Sandra Kang, Alex John Liu, Cassia R. Griswold, Benjamin Edward Ueberroth, Bhamini Patel, Amber Draper, Kelley Rone, Puneet Raman, Tanios S. Bekaii-Saab, Daniel H. Ahn
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Pharmacology & Pharmacy
Daniel Ahn, Daniel Walden, Tanios Bekaii-Saab
Summary: HER-2 plays an important role in different types of cancers, including gastroesophageal, breast, and colorectal cancer. Tucatinib, as a selective HER-2 inhibitor, has shown potential therapeutic effects in a clinical setting. Although its role as a biomarker for prognosis in colorectal cancer remains uncertain, it is still a potential therapeutic target.
EXPERT OPINION ON INVESTIGATIONAL DRUGS
(2022)